See more : E-Home Household Service Holdings Limited (EJH) Income Statement Analysis – Financial Results
Complete financial analysis of Benitec Biopharma Inc. (BNTC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Benitec Biopharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SideChannel, Inc. (SDCH) Income Statement Analysis – Financial Results
- My Screen Mobile, Inc. (MYSL) Income Statement Analysis – Financial Results
- Dalian Sunasia Tourism Holding CO.,LTD (600593.SS) Income Statement Analysis – Financial Results
- Regal Rexnord Corporation (RRX) Income Statement Analysis – Financial Results
- Starpharma Holdings Limited (SPHRY) Income Statement Analysis – Financial Results
Benitec Biopharma Inc. (BNTC)
About Benitec Biopharma Inc.
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 216.00K | 75.00K | 73.00K | 59.00K | 97.00K | 11.32M | 455.45K | 450.31K | 346.51K | 829.13K | 1.02M | 545.73K |
| Cost of Revenue | 108.00K | 381.00K | 9.00K | 123.00K | 268.07K | 426.51K | 331.30K | 209.02K | 103.80K | 30.68K | 37.66K | 176.13K |
| Gross Profit | 108.00K | -306.00K | 64.00K | -64.00K | -171.07K | 10.89M | 124.15K | 241.29K | 242.70K | 798.45K | 980.10K | 369.60K |
| Gross Profit Ratio | 50.00% | -408.00% | 87.67% | -108.47% | -176.36% | 96.23% | 27.26% | 53.58% | 70.04% | 96.30% | 96.30% | 67.73% |
| Research & Development | 15.61M | 12.77M | 11.27M | 7.02M | 3.00M | 2.17M | 5.06M | 5.32M | 9.92M | 4.78M | 5.86M | 3.43M |
| General & Administrative | 6.71M | 6.38M | 6.65M | 6.51M | 5.57M | 6.66M | 6.41M | 6.99M | 8.96M | 6.17M | 7.67M | 4.39M |
| Selling & Marketing | 277.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.99M | 6.38M | 6.65M | 6.51M | 5.57M | 6.66M | 6.41M | 6.99M | 8.96M | 6.17M | 7.67M | 4.39M |
| Other Expenses | -216.00K | -30.00K | -79.00K | 37.00K | -5.00K | 154.77K | 734.59 | -7.91M | -2.68M | -2.14M | -2.18M | -708.18K |
| Operating Expenses | 22.38M | 19.16M | 17.92M | 13.53M | 8.56M | 8.99M | 8.68M | 4.40M | 16.20M | 8.80M | 11.35M | 7.11M |
| Cost & Expenses | 22.49M | 19.16M | 17.93M | 13.66M | 8.38M | 9.41M | 9.01M | 4.61M | 16.31M | 8.84M | 11.38M | 7.28M |
| Interest Income | 0.00 | 49.55K | 46.35K | 0.00 | 62.00K | 119.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 904.00K | 33.00K | 32.00K | 6.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 381.00K | 392.00K | 424.00K | 374.00K | 154.77K | 142.51K | 166.75K | 11.54M | 74.40K | 4.50M | 1.52M |
| EBITDA | -22.49M | -18.70M | -17.85M | -13.60M | -7.91M | 2.74M | -8.59M | -4.19M | -13.42M | -7.93M | -9.90M | -6.64M |
| EBITDA Ratio | -10,412.04% | -24,973.33% | -24,565.75% | -22,506.78% | -8,059.79% | 19.07% | -1,846.62% | -840.79% | -3,872.42% | -857.54% | -972.53% | -1,215.89% |
| Operating Income | -22.49M | -19.08M | -17.85M | -13.60M | -8.28M | 2.00M | -8.55M | -15.92M | -24.96M | -13.33M | -14.40M | -8.16M |
| Operating Income Ratio | -10,412.04% | -25,441.33% | -24,457.53% | -23,044.07% | -8,537.11% | 17.70% | -1,877.75% | -3,536.22% | -7,204.20% | -1,607.59% | -1,414.88% | -1,494.87% |
| Total Other Income/Expenses | 120.00K | -481.00K | -354.00K | -286.00K | 7.00K | 606.03K | 179.24K | 11.55M | 6.46M | 4.50M | 3.56M | 1.32M |
| Income Before Tax | -22.37M | -19.56M | -18.21M | -13.88M | -8.27M | 2.87M | -8.55M | -4.37M | -18.50M | -8.83M | -10.84M | -6.84M |
| Income Before Tax Ratio | -10,356.48% | -26,082.67% | -24,942.47% | -23,528.81% | -8,529.90% | 25.34% | -1,877.42% | -970.99% | -5,340.09% | -1,064.66% | -1,064.66% | -1,253.01% |
| Income Tax Expense | -619.00K | 3.00K | 354.00K | -101.00K | 27.00K | -864.22K | 1.47K | 209.79K | -9.00M | 821.46K | -4.03M | -414.32K |
| Net Income | -21.75M | -19.56M | -18.56M | -13.78M | -8.30M | 2.87M | -8.55M | -4.37M | -18.50M | -8.83M | -10.84M | -6.42M |
| Net Income Ratio | -10,069.91% | -26,082.67% | -25,427.40% | -23,357.63% | -8,557.73% | 25.34% | -1,877.42% | -970.99% | -5,340.09% | -1,064.66% | -1,064.66% | -1,177.09% |
| EPS | -5.36 | -14.12 | -38.62 | -54.54 | -138.19 | 56.89 | -207.21 | -127.11 | -663.12 | -389.77 | -611.08 | -1.45K |
| EPS Diluted | -5.36 | -14.12 | -38.62 | -54.54 | -138.19 | 56.89 | -207.21 | -127.11 | -663.12 | -389.77 | -611.08 | -1.45K |
| Weighted Avg Shares Out | 4.06M | 1.39M | 480.69K | 252.67K | 60.07K | 50.40K | 41.27K | 34.40K | 27.90K | 22.65K | 17.73K | 4.43K |
| Weighted Avg Shares Out (Dil) | 4.06M | 1.39M | 480.69K | 252.67K | 60.07K | 50.40K | 41.27K | 34.40K | 27.90K | 22.65K | 17.73K | 4.43K |
Financial Analysis: Netflix (NASDAQ:NFLX) vs. BB Liquidating (NASDAQ:BLIBQ)
Netflix (NASDAQ:NFLX) and BB Liquidating (OTCMKTS:BLIBQ) are both consumer discretionary companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk. Insider...
Weekly Summary Corporate dividends, name changes, new listings
NEW YORK (AP) — Changes announced in corporate dividends Apr. 13-Apr. 17. INCREASED DIVIDENDS First Republic Bank .20 from .19 Johnson & Johnson 1.01 from .95 Procter & Gamble .7907 from .7459 REDUCED DIVIDENDS AGNC Investment .12(M) from .16(M) Apache...
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 27) Global Cord Blood Corp (NYSE: CO ) Cleveland BioLabs, ...
Source: https://incomestatements.info
Category: Stock Reports